Nearly 80% of adults living with diabetes report experiences of diabetes stigma. We aimed to examine associations between diabetes stigma and the use of diabetes technologies among adults with type 1 diabetes (T1D). In August 2022, 594 adults with T1D (mean age: 55±15 years; duration T1D: 29±17 years; 71% women) from the dQ&A US Patient Panel completed an online survey. Questions included the Type 1 Diabetes Stigma Assessment Scale (DSAS-1) and diabetes and demographic characteristics. DSAS-1 Total and subscale (Treated Differently, Blame and Judgment, Identity Concerns) scores were compared by device use (independent samples t-test). Individuals who did not use diabetes technologies reported greater stigma (Total; Treated Differently; Identity Concerns) but did not differ from those using technologies on Blame and Judgment (Table). The relationship between diabetes stigma and technology use is a novel finding, warranting further investigation with larger, more heterogeneous samples to determine whether diabetes stigma may be a barrier to device use or whether it is mitigated by device use.

Disclosure

M.Garza: Other Relationship; Sanofi. E.Shoger: Other Relationship; Dexcom, Inc., Abbott Diabetes, Tandem Diabetes Care, Inc., Beta Bionics, Inc., Xeris Pharmaceuticals, Inc., MannKind Corporation. E.Holmes-truscott: Research Support; Sanofi, AstraZeneca. K.Joiner: None. A.Addala: None. D.Naranjo: None. E.A.Beverly: None. J.Speight: Research Support; Sanofi, Medtronic, Abbott Diabetes, Lilly, Novo Nordisk A/S, Speaker's Bureau; Sanofi.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.